Notably, the 2026 edition marked the 50th anniversary of this event and attracted a large, diverse audience, including healthcare professionals, diagnostic companies, and technology providers.
Mediq’s booth was strategically positioned near one of the main exhibition entrances, ensuring excellent visibility and continuous visitor flow. Here, for the first time in Finland, we showcased the latest technology in blood gas testing: the GEM Premier 7000 — the unique blood gas analyzer with integrated hemolysis detection on whole blood. The solution raised significant interest throughout the booth, where, together with our partners, we conducted live demonstrations for the attendees.
On the second day, Mediq sponsored two Werfen scientific sessions, offering us an even larger platform to present the newly launched GEM Premier 7000 and ASTELIA, the Bayesian QC Module that completes and enriches the ACL TOP 70 Series offering. Both sessions were well attended and aligned with current market trends, especially the growing clinical interest in hemolysis detection directly at the point-of-care and the demand for advanced tools in analytical Quality Controls.
The GEM Premier 7000 session represented a great opportunity to discuss with a laboratory‑focused audience the clinical impact of undetected hemolysis and the increasing urgent need for solutions capable of detecting hemolysis directly at the point-of-care, underlying the value of the GEM Premier 7000.
Interest in Bayesian QC was especially noteworthy, and Prof. Tsiamyrtis’s speech filled the room to capacity, underscoring a clear shift in the market toward novel QC strategies and more sophisticated trend analysis.
Overall, our presence at Labquality Days provided further visibility for both Mediq and Werfen, reinforcing our shared commitment to driving quality and innovation in laboratory medicine and point-of-care.
Sara Sampietro and Arianna Strazzella